Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme

Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. 
Acta Neurol Scand: 122: 159–167.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard.

[1]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[2]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[3]  Wei Huang,et al.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. , 2003, Journal of neurosurgery.

[4]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[5]  A. Brodbelt,et al.  ‘Recurrent’ glioblastoma multiforme, when should we reoperate? , 2008, British journal of neurosurgery.

[6]  A. Sloan,et al.  Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. , 2008, Journal of neurosurgery.

[7]  R. Martuza,et al.  The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma , 2008, Journal of Neuro-Oncology.

[8]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[9]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[10]  Timothy C. Ryken,et al.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery , 2008, Journal of Neuro-Oncology.

[11]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[12]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[13]  M. Shigemori,et al.  Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. , 2007, Surgical neurology.

[14]  M. Prados,et al.  Radiation response and survival time in patients with glioblastoma multiforme. , 1996, Journal of neurosurgery.

[15]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[16]  D. Scheie,et al.  Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile? , 2009, Acta neurologica Scandinavica.

[17]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[18]  G. Becker,et al.  Is older age associated with a worse prognosis due to different patterns of care? , 2005, Cancer.

[19]  Scott VandenBerg,et al.  Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. , 2007, Neuro-oncology.

[20]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[21]  W. Vandertop,et al.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. , 2008, Surgical neurology.

[22]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[23]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[24]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[25]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[26]  H. Mehdorn,et al.  Glioblastoma—the consequences of advanced patient age on treatment and survival , 2006, Neurosurgical Review.

[27]  R. Hatlevoll,et al.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.

[28]  A. Brandes,et al.  Treatment options for recurrent glioblastoma: pitfalls and future trends , 2009, Expert review of anticancer therapy.

[29]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.